

Adam J Schoenfeld

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3661726/adam-j-schoenfeld-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,147
citations

17
h-index

33
g-index

35
ext. papers

1,835
ext. citations

9.3
avg, IF

5.25
L-index

#	Paper	IF	Citations
30	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2899-2909	12.9	11
29	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with Exon 20 Insertions. <i>Clinical Cancer Research</i> , 2021 , 27, 2920-2927	12.9	18
28	How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?. <i>Cancer Journal (Sudbury, Mass)</i> , 2021 , 27, 134-142	2.2	0
27	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. <i>Nature Communications</i> , 2021 , 12, 3697	17.4	5
26	ROS1-dependent cancers - biology, diagnostics and therapeutics. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 35-55	19.4	36
25	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade 2021 , 9,		3
24	SMARCA4 inactivation promotes lineage-specific transformation and early metastatic features in the lung. <i>Cancer Discovery</i> , 2021 ,	24.4	3
23	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. <i>JAMA Oncology</i> , 2020 , 6, 1048-1054	13.4	48
22	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by Fusions. <i>Clinical Cancer Research</i> , 2020 , 26, 2932-2945	12.9	14
21	Acquired Resistance to Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020 , 37, 443-455	24.3	138
20	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 258-265	8.9	32
19	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 231-247	8.9	82
18	The Genomic Landscape of Alterations and Associations with Outcomes in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 5701-5708	12.9	38
17	Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers-Reply. <i>JAMA Oncology</i> , 2020 , 6, 1983	13.4	3
16	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3287-3295	12.9	26
15	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in -Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2654-2663	12.9	103
14	Acquired Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	15

13	Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 802-815	8.9	38
12	Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. <i>Annals of Oncology</i> , 2019 , 30, 839-844	10.3	118
11	Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with G12D-mutant lung cancers. <i>Journal of Physical Education and Sports Management</i> , 2019 , 5,	2.8	15
10	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1530-1538	8.9	43
9	The Value of Using Registries to Evaluate Randomized Clinical Trial Study Populations. <i>JAMA Internal Medicine</i> , 2017 , 177, 889	11.5	4
8	Eliminating Unnecessary Processes in Primary Care. <i>JAMA Internal Medicine</i> , 2016 , 176, 1722-1723	11.5	
7	The Challenges of Mobile Health Regulation. <i>JAMA Internal Medicine</i> , 2016 , 176, 704-5	11.5	11
6	Variation in Quality of Urgent Health Care Provided During Commercial Virtual Visits. <i>JAMA Internal Medicine</i> , 2016 , 176, 635-42	11.5	45
5	The Search for Better Patient Handoff Tools. <i>JAMA Internal Medicine</i> , 2016 , 176, 1402-3	11.5	
4	Pure germinomas of the central nervous system: treatment strategies and outcomes. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 643-9	4.8	10
3	Synthesis, Structure, Dynamics, and Selective Methylation of Platinum and Palladium Diphosphametallacyclobutane Complexes. <i>Organometallics</i> , 2012 , 31, 5573-5585	3.8	9
2	The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. <i>Journal of Neuro-Oncology</i> , 2012 , 108, 133-9	4.8	107
1	Effects of Linker Length on the Rate and Selectivity of Platinum-Catalyzed Asymmetric Alkylation of the Bis(isitylphosphino)alkanes IsHP(CH ₂) _n PHIs (Is = 2,4,6-(i-Pr) ₃ C ₆ H ₂ , n = 1B). <i>Organometallics</i> , 2010 , 29, 2465-2473	3.8	19